Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648207 | 0.93 | ACMSD (0.46) | ACMSDKCNH2HRH3HDAC1HDAC2 | |
| SCHEMBL10793646 | 0.91 | ACMSD (0.45) | ACMSDKCNH2HRH3HDAC1HDAC2 | |
| SCHEMBL2761444 | 0.91 | ACMSD (0.45) | ACMSDKCNH2HRH3HDAC1HDAC2 | |
| SCHEMBL29111655 | 0.91 | ACMSD (0.45) | ACMSDKCNH2HRH3HDAC1HDAC2 | |
| SCHEMBL28019816 | 0.82 | — | — | |
| SCHEMBL1598318 | 0.77 | ACMSD (0.36) | ACMSDKCNH2HRH3PPARAPTGS2 | |
| SCHEMBL360448 | 0.75 | ACMSD (0.47) | ACMSDKCNH2HRH3PPARAPTGS2 | |
| SCHEMBL10793933 | 0.74 | ACMSD (0.53) | ACMSDKCNH2HRH3HDAC1HDAC2 | |
| SCHEMBL604266 | 0.73 | TYMP (0.40) | ACMSDKCNH2HRH3PDGFRBPDGFRA | |
| SCHEMBL15048839 | 0.73 | TYMP (0.40) | ACMSDKCNH2HRH3PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101610995-A | Novel glucagon receptor antagonists | METABASIS THERAPEUTICS INC (US) | 2009-12-23 | — | — | CN | claimed |
| EP-0828736-B1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2003-07-30 | — | — | EP | claimed |
| US-20030119886-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | claimed |
| US-6337377-B1 | CATALYTIC ADDITION POLYMERIZATION OF OLEFIN | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2002-01-08 | — | — | US | claimed |
| US-6127303-A | A COORDINATION CATALYST FOR FORMING TWO ISOTACTIC STEREO-IRREGULAR HOMOPOLYMERS, BASED ON COMPOUNDS OF MAGNESIUM, TITANIUM, HALOGEN, AN ALKYL DIETHER, SILICON ESTER, AND ORGANOALUMINUM; PACKAGING; STRETCHING | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-10-03 | — | — | US | claimed |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021078132-A1 | INHIBITORS OF MTOR-MEDIATED INDUCTION OF AUTOPHAGY | SIRONAX LTD (GB) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021027943-A1 | PYRIMIDINOPYRIDAZINONE DERIVATIVE AND MEDICAL USE THEREOF | 正大天晴药业集团南京顺欣制药有限公司 | 2021-02-18 | — | — | WO | disclosed |
| WO-2017116702-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL, INC. (US) | 2017-07-06 | — | — | WO | disclosed |
| CN-105566265-A | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS INC | 2016-05-11 | — | — | CN | disclosed |
| CN-101610995-A | Novel glucagon receptor antagonists | METABASIS THERAPEUTICS INC (US) | 2009-12-23 | — | — | CN | disclosed |
| EP-0828736-B1 | SUBSTITUTED SULFONYLPHENYLHETEROCYCLES AS CYCLOOXYGENASE-2 AND 5-LIPOXYGENASE INHIBITORS | SEARLE & CO (US) | 2003-07-30 | — | — | EP | disclosed |
| US-4282171-A | Phosphorus and sulfur containing amides and thioamides | THE LUBRIZOL CORPORATION (US) | 1981-08-04 | — | — | US | disclosed |
| US-4208357-A | Process for preparing phosphorus and sulfur containing amides and thioamides | THE LUBRIZOL CORPORATION (US) | 1980-06-17 | — | — | US | disclosed |
| US-4032461-A | PHOSPHORUS AND SULFUR CONTAINING AMIDES AND THIOAMIDES AS LUBRICATING OIL ADDITIVES AND LUBRICATING OIL COMPOSITIONS CONTAINING SAME | THE LUBRIZOL CORPORATION (US) | 1977-06-28 | — | — | US | disclosed |
| US-4031023-A | Lubricating compositions and methods utilizing hydroxy thioethers | THE LUBRIZOL CORPORATION (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | ACMSD 487/4885KCNH2 3777/4885HRH3 1074/4885 |
| US-20030119886-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | ACMSD 910/4885KCNH2 4466/4885HRH3 917/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | ACMSD 994/4885KCNH2 2849/4885HRH3 1321/4885 |
| US-11230571-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | ACMSD 994/4885KCNH2 2849/4885HRH3 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.